Agios Pharmaceuticals Inc
Research Agios Pharmaceuticals Inc (AGIO) on Bullrun: market cap USD 2.02B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAGIO
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 2.02B
- Financial periodQ2 2026
- RevenueUSD 44.75M
- Net income-USD 100.70M
- Free cash flow-USD 83.52M
- Gross margin93.3%
Valuation Snapshot
latest market cap is USD 2.02B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 54.03M | -USD 413.00M | -USD 377.29M | 88.3% | -7.12 | USD 89.13M | USD 40.21M | USD 1.19B |
| FY2024 | USD 36.50M | USD 674.00M | -USD 391.53M | 88.6% | 11.64 | USD 76.25M | USD 56.99M | USD 1.54B |
| FY2023 | USD 26.82M | -USD 352.00M | -USD 297.06M | 89.3% | -6.33 | USD 88.21M | USD 72.00M | USD 811.02M |
| FY2022 | USD 14.24M | -USD 232.00M | -USD 314.36M | 88.0% | -4.23 | USD 139.26M | USD 91.17M | USD 1.10B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 2.02B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 1.59B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.88B | 2.9 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.24B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.54B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.79B | n/a | n/a | n/a |
About Agios Pharmaceuticals Inc
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Agios Pharmaceuticals Inc's market cap?
Agios Pharmaceuticals Inc's market capitalization is USD 2.02B.
What does Agios Pharmaceuticals Inc do?
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency.